Pharmac Consultation

Proposal to fund medicines for multiple sclerosis, eye conditions, breast cancer and lung cancer

Pharmac is seeking feedback on a proposal to fund five medicines through a multiproduct agreement with Roche. These medicines would provide new or improved treatment options for people with multiple sclerosis, breast cancer, eye conditions, and lung cancer.

The medicines we are proposing to fund are:

•         Faricimab (Vabysmo): for diabetic macular oedema and wet

           age-related macular degeneration (eye conditions)

•         Entrectinib (Rozlytrek): for ROS1-positive non-small cell lung

           cancer

•         Ocrelizumab (Ocrevus SC): a new injection option for multiple

           sclerosis

•         Pertuzumab with trastuzumab (Phesgo): a new combined

           injection for HER2-positive metastatic breast cancer

•         Bevacizumab (Avastin): securing ongoing access for people with

           eye conditions

If approved, these medicines would be funded from 1 December 2025.  

Proposal to fund medicines for multiple sclerosis, eye conditions, breast cancer and lung cancer

We welcome your feedback. Consultation is open until 5:00pm 8 October 2025. To provide feedback please use the online form linked in the consultation.

Ngā mihi,

 Emma Clarke | Senior Therapeutic Group Manager

Josh Wiles | Senior Therapeutic Group Manager / Team Leader

Pharmac | Te Pātaka Whaioranga | PO Box 10 254 | Level 9, 40 Mercer Street, Wellington P: 0800 660 050 | www.pharmac.govt.nz